RT Journal Article
SR Electronic
T1 O8 Randomised controlled trial of antibiotic/hydroxychloroquine combination versus standard budesonide in active Crohn’s disease (APRICOT)
JF Gut
JO Gut
FD BMJ Publishing Group Ltd and British Society of Gastroenterology
SP A4
OP A5
DO 10.1136/gutjnl-2020-bsgcampus.8
VO 70
IS Suppl 1
A1 Rhodes, Jonathan
A1 Subramanian, Sreedhar
A1 Flanagan, Paul
A1 Horgan, Graham
A1 Martin, Kate
A1 Mansfield, John
A1 Parkes, Miles
A1 Hart, Ailsa
A1 Dallal, Helen
A1 Iqbal, Tariq
A1 Butterworth, Jeff
A1 Culshaw, Kate
A1 Probert, Christopher
YR 2021
UL http://gut.bmj.com/content/70/Suppl_1/A4.2.abstract
AB Introduction Mucosal E. coli are increased in Crohn’s disease (CD). They replicate within macrophages and are then inaccessible to penicillins and gentamicin. Hydroxychloroquine is used with doxycycline to treat Whipple’s disease. It raises macrophage intra-vesicular pH and inhibits replication of bacteria that require acidic pH. Ciprofloxacin and doxycycline are also effective against E. coli within macrophages.Methods Adult patients with active CD (CDAI>220 plus CRP≥5 mg/l and/or faecal calprotectin >250 ugram/g) were randomised to receive (open label) either oral budesonide (Entocort CR 9 mg/day 8 weeks, then 6 mg/day 2 weeks and 3 mg/day 2 weeks) or antibiotics/hydroxychloroquine (AB/HCQ) - oral ciprofloxacin 500 mg bd, doxycycline 100 mg bd, hydroxychloroquine 200 mgs tds for 4 weeks, followed by doxycycline 100 mg bd and hydroxychloroquine 200 mgs tds for 20 weeks. Use of anti-TNF in the previous 3 months was an exclusion. Primary endpoints were remission (CDAI </=150) at 10 weeks, remission maintained to 24 weeks, and remission maintained to 52 weeks. Patients not responding by 10 weeks were invited to cross-over onto the alternative therapy.Results 59 patients were recruited across 8 sites, lower than target (100) as recruitment slowed due to widening access to biologics. Including cross-over, 39 patients received AB/HCQ and 39 received budesonide. No significant differences were seen comparing AB/HCQ with budesonide at 10, 24 or 52 weeks on either intention-to-treat or per protocol analysis (see table 1). Withdrawals by 10 weeks due to adverse events were seen in 16 AB/HCQ and 7 budesonide. When patients on AB/HCQ who responded at 10 weeks and later remitted were included, 9/24 patients were in remission at 24 weeks and 4/23 at 52 weeks. No correlation was seen between response to AB/HCQ and ASCA/OmpC status.View this table:Abstract O8 Table 1 Per protocol outcomes, including cross-over (Primary endpoints in bold)Conclusions The long term remissions seen with AB/HCQ are encouraging and justify a phase 3 study.